Rising Demand for Surgical Interventions for Treating Cardiovascular Disorders to Surge Fluorescence Guided Surgery System Market at 15.5% CAGR by 2034 | Future Market Insights, Inc.
09. Juli 2024 12:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, July 09, 2024 (GLOBE NEWSWIRE) -- According to Future Market Insights (FMI), the global fluorescence-guided surgery system market is projected to reach USD 110.8 million in 2024 and USD...
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
12. Januar 2021 10:10 ET
|
NX Development Corp.
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)
17. November 2020 14:12 ET
|
NX Development Corp.
Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization
03. Oktober 2019 12:58 ET
|
NX Development Corp.
Lexington, KY, Oct. 03, 2019 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company based in Lexington, KY, today announced Baptist Health Lexington is the first hospital in state...